Only a handful of cancer patients respond to anti-PD-L1 checkpoint inhibitor therapy, but why? The answer lies in their genes. In this webinar, discover how bioinformatic analysis of the multi-omics data of 298 cancer patients resulted in identification of the predictive biomarkers linked to therapeutic success.
Learn how mining big data can help accurately stratify patients who will respond to your therapy, driving decisions and allowing you to bring your best anti-cancer therapies further into development.
Max Bylesjo, PhD, MSc
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digitaleducation.